Lamivudine / Zidovudine ViiV (previously Lamivudine / Zidovudine GSK) - opinion on medicine for use outside EU
lamivudine / zidovudine
EU-M4allHuman
Overview
The opinion for Lamivudine / Zidovudine ViiV for use outside the European Union has been withdrawn at the request of the opinion holder.
Product information
Latest procedure affecting product information: H-W-672-WS-0755
17/09/2015
Product information documents contain:
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturer responsible for batch release
- Annex IIB - Recommendations to the opinion holder - conditions of use
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Pharmacotherapeutic group
Antivirals for systemic useTherapeutic indication
Lamivudine/zidovudine is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (HIV) infected adults and children.
Opinion details
Product details
- Name of medicine
- Lamivudine / Zidovudine ViiV (previously Lamivudine / Zidovudine GSK)
- EMA opinion number
- H/W/672
- Opinion status
- Withdrawn opinion
- Active substance
- lamivudine
- zidovudine
- International non-proprietary name (INN) or common name
- lamivudine
- zidovudine
- Therapeutic area (MeSH)
- HIV Infections
- Anatomical therapeutic chemical (ATC) code
- J05AR01
Publication details
- Opinion holder
- ViiV Healtcare UK Limited
980 Great West Road
Brentford
Middlesex TW8 9GS
United Kingdom - Date of opinion